Gilead's HIV Prevention Treatment Lenacapavir Shows Potential

Gilead Sciences, Inc. (GILD) recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the prevention of HIV. Data reinforce that twice-yearly lenacapavir could be a highly effective and potentially game-changing HIV prevention option. Additional Data From GILD's HIV Study The double-blind, multicenter, randomized study phase III study, PURPOSE 2, is evaluating the safety and efficacy of twice-yearly su ...